RxDoctor Payments Data

David Sonego, MD

Psychiatry · Mishawaka, INNPI 1861496432

Payments from drug & device makers

$4,816in general payments, 2019–2025

Across 277 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tris Pharma Inc$969
  • Otsuka America Pharmaceutical, Inc.$660
  • Ironshore Pharmaceuticals Inc.$540
  • Vanda Pharmaceuticals Inc.$338
  • Corium, LLC$285
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$278
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$4,805100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,816 in reported general payments places this provider in the 85th percentile of 514 psychiatry providers in Indiana.

See all psychiatry providers in Indiana

Medicare billing

Part B allowed, 2024
$57,838
Medicare patients
92
Services billed
601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvanseLisdexamfetamine Dimesylate28$15,703
LexaproEscitalopram Oxalate15$10,609
Lisdexamfetamine Dimesylate32$7,203
Dyanavel XrAmphetamine12$4,865
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine61$4,673
Zaleplon42$3,191
Bupropion XlBupropion Hcl117$2,289
Escitalopram Oxalate193$1,976
Methylphenidate ErMethylphenidate Hcl19$1,921
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine49$1,714
Trazodone Hcl175$1,546
Bupropion Hcl SrBupropion Hcl72$1,136
Divalproex Sodium ErDivalproex Sodium15$995
Paroxetine Hcl105$845
Quetiapine Fumarate47$803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$159$15,70328 claims
AbbVieLexapro$253$10,60915 claims
Tris Pharma IncDyanavel Xr$969$4,86512 claims
Almatica Pharma LLCSertraline Hcl$183$21148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 514 psychiatry providers in Indiana.

Other psychiatry in Mishawaka

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →